Trulicity is a once-weekly diabetes injection.
Its active ingredient is dulaglutide, a GLP-1 receptor agonist made by Eli Lilly. The FDA cleared dulaglutide (Trulicity) for type 2 diabetes in 2014, and in 2020 it became the first GLP-1 with a label claim for reducing major adverse cardiovascular events in adults with T2D, with or without established heart disease. If you came here trying to figure out how Trulicity actually works, what dulaglutide does to A1C and weight, and how it stacks up against newer injections like Ozempic and Mounjaro, this is a straight answer.
🔑 Key Takeaways
- Dulaglutide is the generic name for Trulicity, a once-weekly GLP-1 injection from Eli Lilly approved for type 2 diabetes.
- Doses step up from 0.75 mg to 1.5 mg, then 3 mg and 4.5 mg if A1C is not at goal. Higher doses give more A1C lowering, not just more weight loss.
- The REWIND trial showed a 12% relative reduction in major cardiovascular events over a median 5.4 years, including in people without prior heart disease.
- Weight loss with Trulicity is real but modest, typically 3 to 5% of body weight, far below what semaglutide and tirzepatide deliver.
- Trulicity is not FDA approved for weight loss. If your goal is weight loss alone, dulaglutide is the wrong tool.
What dulaglutide (Trulicity) is
Trulicity is a long-acting GLP-1.
Dulaglutide is a fusion protein. It joins two modified GLP-1 peptide chains to a human IgG4 antibody fragment, which slows breakdown and lets you dose once a week instead of daily. It binds the GLP-1 receptor and does what natural GLP-1 does, just for seven days at a time: it pushes the pancreas to release insulin only when blood sugar is high, blunts glucagon, slows stomach emptying, and quiets appetite signals in the brain.
Trulicity comes in a single-use pen you press against your skin. You do not see the needle. You inject once a week, on the same day, into the belly, thigh, or upper arm.
The basics in a line: Trulicity is the brand name, dulaglutide is the molecule, Eli Lilly is the maker, and the primary FDA approval is for type 2 diabetes in adults and in children 10 and older. For background on the broader drug class, see our explainer on what GLP-1 is and how it works.
Trulicity dosing schedule
Dosing is simple by design.
You start low and titrate up only if your blood sugar is not controlled. The pens are single-strength and disposable, so each dose is one pen.
| Dulaglutide dose | Frequency | When it is used |
|---|---|---|
| 0.75 mg | Once weekly | Starting dose for some patients, including those sensitive to GI side effects |
| 1.5 mg | Once weekly | Standard maintenance dose, used by most people on Trulicity |
| 3 mg | Once weekly | Step up after at least 4 weeks on 1.5 mg if A1C is still high |
| 4.5 mg | Once weekly | Maximum dose, after at least 4 weeks at 3 mg |
Inject on the same day each week. If you forget a dose and the next scheduled dose is at least 3 days (72 hours) away, take the missed dose right away. If less than 3 days are left, skip it and take the next one on schedule. Do not double up.
Trulicity goes in the fridge until first use, then it can sit at room temperature up to 14 days. Past 14 days out of the fridge, throw the pen out.
What Trulicity is approved for
Two FDA approvals matter.
The first is glycemic control in type 2 diabetes, alongside diet and exercise. The second is a cardiovascular risk reduction claim, added in 2020. Trulicity can lower the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes who either have established heart disease or multiple risk factors. That second indication is unusual. Most GLP-1 cardiovascular trials only enrolled people who already had a heart event. Dulaglutide is the one that proved benefit in primary prevention too.
Trulicity is not approved for type 1 diabetes, diabetic ketoacidosis, or weight loss. Doctors sometimes still prescribe it off-label when weight loss is a side goal, but the better-suited weight loss drugs are semaglutide (Wegovy) and tirzepatide (Zepbound).
The REWIND cardiovascular trial
REWIND is the reason Trulicity has a heart claim.
It enrolled 9,901 adults with type 2 diabetes and either prior cardiovascular disease or multiple risk factors. About 69% had no prior cardiovascular event when they started, which is why people call it a primary prevention trial. Median follow-up was 5.4 years. Patients took 1.5 mg dulaglutide weekly or placebo, on top of standard care.
Major cardiovascular events fell from 13.4% on placebo to 12.0% on Trulicity, a hazard ratio of 0.88. That is a 12% relative reduction. Stroke specifically dropped by 24%. There was also a slower decline in kidney function and lower rates of new macroalbuminuria. Mortality alone did not change significantly, but the composite endpoint did, and that is the bar the FDA used.
For someone with type 2 diabetes who is also worried about cardiovascular risk, dulaglutide has the strongest primary prevention data of any GLP-1 currently on the market.
How much weight do you lose on Trulicity
Less than you might think.
Across the AWARD trials, average weight loss on Trulicity 1.5 mg was about 3 kg (6 to 7 lb) over 6 to 12 months. The 4.5 mg dose, tested in AWARD-11, brought average loss closer to 4.6 kg (about 10 lb). In percentage terms, that is roughly 3 to 5% of body weight for most people.
Compare that to semaglutide 2.4 mg (Wegovy) at around 15% body weight loss in STEP-1, or tirzepatide 15 mg (Zepbound) at around 21% in SURMOUNT-1, and the gap is obvious. Trulicity is a diabetes drug that nudges weight down. Wegovy and Zepbound are weight loss drugs that also help blood sugar. If your A1C is the priority, Trulicity is fine. If a 20-pound loss is the goal, it is the wrong pick.
For a broader ranked view of options, see our roundup of the best peptides for weight loss.
Dulaglutide vs Ozempic vs Mounjaro
This is the question most people land here for.
| Trulicity (dulaglutide) | Ozempic (semaglutide) | Mounjaro (tirzepatide) | |
|---|---|---|---|
| Class | GLP-1 agonist | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Frequency | Once weekly | Once weekly | Once weekly |
| Dose range | 0.75 to 4.5 mg | 0.25 to 2 mg | 2.5 to 15 mg |
| Typical A1C drop | ~1.1 to 1.5% | ~1.5 to 1.8% | ~2.0 to 2.4% |
| Typical weight loss (T2D) | ~3 to 5% | ~6% | ~10 to 12% |
| FDA cardiovascular claim | Yes, primary + secondary prevention | Yes, secondary prevention | No (CV trial pending) |
| Pen design | Pre-loaded, hidden needle | Multi-dose pen, visible needle | Single-use pen |
Trulicity wins on simplicity (hidden needle, one-press pen) and on primary prevention CV data. Ozempic wins on slightly stronger A1C control with a smaller pen footprint and a richer real-world evidence base. Mounjaro wins clearly on both A1C and weight, since adding GIP agonism gives it a metabolic edge dulaglutide does not match.
Switching from Trulicity to something else
Switches are common.
Two situations come up most. First, you are on Trulicity 1.5 mg or 4.5 mg and your A1C is still above target. Switching to semaglutide or tirzepatide often gets you there. The standard approach is to stop dulaglutide, wait one week (so the next dose would have been due), then start the new GLP-1 at its lowest titration dose. You do not get to skip titration, even if you have been on a high dose of dulaglutide, because the new molecule has its own GI side effect curve.
Second, you want more weight loss. Insurance often pushes back here because Trulicity is approved for diabetes and Wegovy/Zepbound are approved for obesity. Your prescriber can document why a switch is medically warranted (cardiovascular risk, BMI, comorbidities) to help with prior authorization.
Side effects
Most are gut-related.
- Common: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, fatigue, indigestion. These usually fade after the first few weeks, especially if doses are titrated slowly.
- Less common: injection site reactions, mild heart rate increases, dehydration from persistent vomiting or diarrhea.
- Serious (rare): pancreatitis, gallbladder disease, severe allergic reactions, acute kidney injury (usually tied to dehydration), low blood sugar when combined with insulin or sulfonylureas, and diabetic retinopathy worsening in people with existing retinopathy.
The boxed warning is for thyroid C-cell tumors. In rodents (one rodent species), dulaglutide caused thyroid tumors. Human relevance is unknown, but Trulicity is contraindicated if you or a family member has medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Cost and coverage
List price stings. Coverage helps.
The list price for Trulicity is around $987 per month for a 4-pen box at any dose. Most commercial insurance plans cover it for type 2 diabetes with a copay between $25 and $200 a month. Eli Lilly runs a savings card program that can drop the cost to as little as $25 a month for eligible commercially insured patients. Without insurance, you are paying close to list. There is no generic dulaglutide on the US market and no clear date for one (Lilly's main patents extend into the late 2020s). If price is the deciding factor, semaglutide and tirzepatide are not cheaper at list, but compounded versions exist for those, while compounded dulaglutide is not really a thing.
Who Trulicity fits
- Type 2 diabetes with cardiovascular risk: if you have multiple CV risk factors but no prior event, dulaglutide has the cleanest primary prevention data.
- People who hate injections: the Trulicity pen hides the needle and works with a single press. It is the friendliest GLP-1 pen on the market.
- Patients on a stable diabetes regimen who need a modest A1C bump: 1.5 mg weekly with no titration headaches.
- Older adults or kidney patients: dulaglutide does not need renal dose adjustments and has decent safety data in CKD.
Who it does not fit
- Anyone whose primary goal is significant weight loss. Pick semaglutide or tirzepatide.
- People with personal or family history of medullary thyroid cancer or MEN 2.
- People with severe gastroparesis or a history of pancreatitis.
- Type 1 diabetes (not approved, not effective for that mechanism).
Medical disclaimer. This article is informational and is not medical advice. Trulicity (dulaglutide) is a prescription medication. Talk to a qualified clinician before starting, stopping, or switching any GLP-1 therapy. Dosing, side effects, and contraindications must be reviewed individually.